AndroGel Pediatric (Under 12) Dosing: What Clinicians and Parents Need to Know

Is AndroGel Approved for Children Under 12?

AndroGel is not approved for any patient under 18, and its prescribing information explicitly lists pediatric use as a contraindication. The FDA strengthened this position in 2009 with a black-box warning after receiving case reports of premature puberty in young children who had skin contact with adults using testosterone gels. No randomized controlled trial has evaluated AndroGel 1% or 1.62% in children under 12 for any indication.

The FDA's 2009 safety communication required all topical testosterone manufacturers, including AbbVie (AndroGel), to add a boxed warning describing virilization in children exposed through secondary skin contact. [1] Reported signs included pubic hair growth, penile or clitoral enlargement, advanced bone age, and aggressive behavior, often appearing within weeks to months of first exposure. [2]

That warning was not a precaution. It was a contraindication. Prescribing AndroGel to a child under 12 falls outside FDA-approved labeling and outside the standard of care as defined by the Pediatric Endocrine Society. [3]

Clinicians treating pediatric hypogonadism or constitutionally delayed puberty use entirely different agents and delivery methods, discussed in detail below.

Why Testosterone Is Sometimes Needed in Children Under 12

Testosterone deficiency in children under 12 is uncommon but real. Causes include primary hypogonadism from conditions such as Klinefelter syndrome (47,XXY, present in approximately 1 in 650 male births) [4], bilateral cryptorchidism with testicular failure, or damage from chemotherapy and radiation. Secondary hypogonadism may arise from hypothalamic or pituitary pathology, including craniopharyngioma or hypopituitarism. [5]

Micropenis diagnosed in infancy represents a separate, short-duration use case. Testosterone cream or injectable testosterone enanthate at 25 mg IM monthly for three months may be used in infancy to confirm androgen responsiveness and to increase penile length before surgical or psychological decision-making. [6] This is distinct from ongoing hypogonadism management.

The Pediatric Endocrine Society states that the decision to initiate testosterone therapy in a boy under 12 must be made by a pediatric endocrinologist who has excluded other treatable causes and confirmed the diagnosis with two fasting morning total testosterone levels below 100 ng/dL alongside appropriately low or normal LH and FSH values. [3]

Children aged 10 to 12 with Klinefelter syndrome show testicular failure progressing rapidly at puberty onset, with mean testosterone levels of 148 ng/dL at Tanner stage II compared with 320 ng/dL in age-matched controls in one observational cohort (N=87). [7] Early recognition matters because bone mineral density, lean mass, and cognitive outcomes are all sensitive to testosterone status during early puberty.

What Does Testosterone Gel Actually Do in the Body?

Testosterone gel is absorbed transdermally through the stratum corneum, delivering testosterone into circulation without first-pass hepatic metabolism. Peak serum levels occur 2 to 8 hours after application in adults. Daily application maintains relatively steady-state serum testosterone, avoiding the supraphysiologic peaks and troughs associated with biweekly intramuscular injections. [8]

In adult males, AndroGel 1.62% at a starting dose of 40.5 mg (2 pump actuations) produces mean steady-state serum testosterone of approximately 560 ng/dL. [9] Dose titration to 20.25 mg or 81 mg allows a target range of 300, 1 to 000 ng/dL per the prescribing information.

None of this pharmacokinetic data was collected in children. Absorption rates, volume of distribution, and metabolic clearance differ substantially between prepubertal children and adult men. Children have thinner skin with higher surface-area-to-weight ratios, meaning that even incidental skin contact, not intentional application, transfers biologically significant testosterone doses. [2] A child weighing 20 kg absorbing even 5% of a standard adult 40.5 mg dose receives approximately 2 mg of testosterone, a dose that may be sufficient to advance bone age meaningfully over several months. [10]

Secondary Exposure: The Hidden Risk for Families

The FDA's 2009 boxed warning emerged from real cases. One widely cited FDA MedWatch summary described a 4-year-old boy who developed pubic hair, penile enlargement, and a bone age of 7 years after his father applied testosterone gel and then held the child before washing his hands and chest. [1]

Secondary exposure can occur through:

• Skin-to-skin contact with an application site that has not dried completely (drying takes 2 to 5 minutes in most adults)
• Shared towels, clothing, or bedding
• Contact with surfaces where gel has transferred

The FDA recommends that patients using any topical testosterone wash hands immediately after application, cover the application site with clothing after the gel dries, and wash the site thoroughly with soap and water before any anticipated skin contact with a child. [1] If a child shows any signs of virilization, the adult caregiver's testosterone therapy should be evaluated as a possible source before other causes are pursued.

Signs of accidental testosterone exposure in a child under 12 include: [2]

• Pubic or axillary hair growth
• Penile or clitoral enlargement
• Acne beyond what is developmentally expected
• Aggressive or mood-altered behavior
• Accelerated linear growth

Bone age X-ray should be obtained promptly if exposure is suspected, because advanced bone age can permanently reduce adult height if treatment is delayed. [10]

Approved and Guideline-Supported Testosterone Treatments for Children Under 12

Because AndroGel is not appropriate for children under 12, pediatric endocrinologists use the following alternatives. Each requires specialist oversight.

Injectable Testosterone Esters

Testosterone enanthate and testosterone cypionate (both generic, Schedule III controlled substances) are the most commonly used forms in pediatric patients. The Pediatric Endocrine Society recommends starting at 25 to 50 mg intramuscularly every 4 weeks for boys with delayed puberty or hypogonadism who require intervention before mid-puberty age. [3] Dosing is increased incrementally over 18 to 24 months to mimic the slow rise of endogenous testosterone during normal puberty.

For boys under 10 with micropenis or proven primary hypogonadism, doses as low as 25 mg IM monthly for 3 to 6 months are used diagnostically and therapeutically. [6] One small prospective study (N=31) confirmed that testosterone enanthate 25 mg IM monthly for 3 months increased stretched penile length by a mean of 1.6 cm without significant bone age advancement when used in infants under 6 months. [11]

Compounded Testosterone Cream or Gel

In some pediatric centers, compounded testosterone cream at concentrations of 2 to 5% is applied to the scrotum in adolescent males who cannot tolerate injections. This is not a standard first-line approach for children under 12, and compounded preparations lack FDA approval. The American Academy of Pediatrics has noted safety concerns about compounding quality variability. [12]

A Practical Decision Framework for Pediatric Testosterone Initiation (Under 12)

Before any testosterone is prescribed for a child under 12, the following sequence should be completed by a board-certified pediatric endocrinologist:

1. Confirm diagnosis: two fasting morning total testosterone values below age-appropriate reference range, paired with LH and FSH to distinguish primary from secondary hypogonadism.
2. Obtain baseline bone age (left-hand X-ray using Greulich-Pyle atlas).
3. Obtain baseline DXA scan if long-term therapy is anticipated, per PES guidance. [3]
4. Select agent: testosterone enanthate 25 to 50 mg IM every 4 weeks is first-line. AndroGel and other approved topical formulations are not appropriate.
5. Set titration schedule: increase dose by 25 to 50 mg increments every 6 months based on pubertal progression (Tanner staging) and serum testosterone levels.
6. Monitor bone age every 6 months and discontinue or reassess if bone age advances more than 1 year ahead of chronological age in a 6-month interval.
7. Measure serum testosterone mid-cycle (approximately 2 weeks after IM injection) targeting 300 to 500 ng/dL during early titration.

This framework is not a substitute for individualized clinical judgment. Every child's growth trajectory, underlying diagnosis, and family circumstances require specialist evaluation.

What the T-Trials Tell Us (and Don't Tell Us)

The NIH-funded Testosterone Trials (T-Trials, N=790) are the largest rigorous placebo-controlled evaluation of testosterone therapy using topical gel formulations. [13] Published in the New England Journal of Medicine in 2016, the T-Trials enrolled men aged 65 and older with serum testosterone below 275 ng/dL and at least one of three syndromic deficiency criteria.

Topical testosterone (AndroGel 1%) raised mean serum testosterone from 232 ng/dL at baseline to 454 ng/dL at 12 months compared with minimal change in the placebo group. [13] This confirms that topical delivery reliably achieves target serum levels in adults with an intact skin barrier and normal dermal absorption.

The T-Trials are frequently cited in discussions of testosterone gel pharmacokinetics. They provide no data on children. The enrolled population was physiologically opposite to a prepubertal child: older, with thinner skin from aging, lower endogenous production, and fully fused growth plates. Extrapolating T-Trials data to children under 12 is not clinically valid.

As the Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We recommend against prescribing testosterone therapy to men anticipating fertility in the near term or to patients with breast or prostate cancer, hematocrit above 54%, or severe lower urinary tract symptoms. We also recommend against testosterone use in children." [14]

Monitoring Parameters When Testosterone Is Used Off-Label in Young Children

If a pediatric endocrinologist determines that testosterone is medically necessary for a child under 12 (typically for primary hypogonadism), monitoring is intensive and non-negotiable. The following schedule reflects PES 2022 recommendations. [3]

Every visit (every 3 to 6 months during therapy):

• Tanner staging (genital and pubic hair)
• Height and weight with growth velocity calculation
• Blood pressure
• Serum total testosterone (timed to injection cycle for injectables)
• Hematocrit or hemoglobin (testosterone stimulates erythropoiesis)
• LH and FSH (to monitor axis suppression and endogenous recovery)

Every 6 months:

• Bone age X-ray (left hand and wrist)
• Reassessment of indication and dose

Annually or at baseline:

• DXA scan for bone mineral density if therapy extends beyond 12 months
• Lipid panel (testosterone can lower HDL cholesterol by approximately 10 to 15% in some pediatric populations) [15]
• Liver function tests if oral androgens are ever used (not applicable to injectable or gel forms, but included in comprehensive panels)

If bone age advances by more than 1.5 years in a 6-month window, dose reduction or suspension is indicated regardless of serum testosterone levels. [3] Loss of predicted adult height is an irreversible consequence of premature growth plate closure, making bone age monitoring the highest-stakes safety parameter in pediatric testosterone therapy.

Preventing Accidental AndroGel Exposure in Households With Young Children

Adults using AndroGel who live with children under 12 must follow specific precautions. The FDA label for AndroGel 1.62% states: "Patients should be instructed to wash their hands with soap and water immediately after application... cover the application site(s) with clothing after the gel has dried, and to wash the application site thoroughly with soap and water prior to any situation in which skin-to-skin contact of the application site with another person is anticipated." [9]

Beyond label guidance, the following practices reduce exposure risk: [1]

• Apply gel at a consistent time when contact with children is 4 to 6 hours away (e.g., morning application before going to work).
• Store AndroGel in a locked medicine cabinet. Children have inadvertently self-applied gel found in accessible bathroom areas.
• Wash sheets and pillowcases weekly if the application site contacts bedding overnight.
• Inform all household caregivers and daycare providers to watch for early virilization signs.

Pediatricians seeing a child with unexplained early puberty should include adult household testosterone gel use in their differential. One analysis of FDA adverse event reports through 2010 identified 24 pediatric cases of virilization attributable to secondary testosterone gel exposure, with a median age of 4 years (range 9 months to 5 years). [2] Many cases were initially attributed to precocious puberty of unknown etiology before the household exposure was identified.

Regulatory and Legal Context

Prescribing AndroGel to a patient under 18 constitutes off-label use. Off-label prescribing is legal in the United States but carries heightened liability when the FDA label contains an explicit contraindication. For children under 12 specifically, prescribing AndroGel could expose a clinician to professional board scrutiny, malpractice liability, and DEA review given testosterone's Schedule III controlled substance classification. [16]

The FDA Pediatric Research Equity Act (PREA) requires manufacturers to study drugs in children when those drugs may be used in pediatric populations. AbbVie has not conducted pediatric trials for AndroGel because the drug is contraindicated in children, an exemption the FDA grants when the risks of pediatric study are unacceptably high relative to potential benefit. [17]

Physicians who believe a child under 12 requires testosterone therapy should document the following in the medical record: specialist consultation with a board-certified pediatric endocrinologist, written informed consent from the guardian including a discussion of the off-label nature of any testosterone preparation used, and the specific clinical rationale distinguishing the chosen preparation from AndroGel.

Compounding Pharmacies and Pediatric Testosterone

Some families, after receiving a pediatric hypogonadism diagnosis, seek compounded testosterone gels or creams from compounding pharmacies as an alternative to injections. The appeal is understandable: gels are painless compared with monthly intramuscular injections in a young child.

The FDA has not approved any compounded testosterone gel for pediatric use. The agency's guidance on compounding states that compounded preparations may be used when a commercially available product is not suitable for a specific patient, for example when a different concentration or formulation is medically necessary. [17] A pediatric endocrinologist prescribing a 1% testosterone cream for scrotal application in a 10-year-old with Klinefelter syndrome could justify this under compounding frameworks, provided a licensed compounding pharmacy following USP 795 or 797 standards prepares the product.

However, quality and potency variability in compounded preparations is real. The FDA's 2013 inspection of compounding pharmacies found that 23 of 29 inspected facilities had at least one significant quality deficiency. [17] For children whose growth trajectories are sensitive to even small variations in testosterone dose, potency variability is a meaningful clinical risk. Injectable testosterone esters from licensed manufacturers remain the more reliable choice for children who genuinely need testosterone therapy before puberty.